Coverage Gaps, Reimbursement Barriers Remain for PDTs

Originally published by our sister publication Specialty Pharmacy ContinuumBy Karen BlumDespite FDA approval, prescription digital therapeutics (PDTs) face persistent coverage and reimbursement barriers across U.S. payors, according to a presentation (poster 120) at AMCP 2025 Nexus, in National Harbor, Maryland.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:bloc